Your browser doesn't support javascript.
loading
PARs in the inflammation-cancer transformation of CRC.
Lv, Jianyu; Liu, Jinguo; Chao, Guanqun; Zhang, Shuo.
Afiliação
  • Lv J; The First Affiliated Hospital, Zhejiang Chinese Medical University, Zhejiang, China.
  • Liu J; The First Affiliated Hospital, Zhejiang Chinese Medical University, Zhejiang, China.
  • Chao G; Department of General Practice, Sir Run Run Shaw Hospital, Zhejiang University, Hanghou, China. chaoguanqun@zju.edu.cn.
  • Zhang S; Department of Gastroenterology, The Second Affiliated Hospital, Zhejiang Chinese Medical University, Zhejiang, China. zhangshuotcm@126.com.
Clin Transl Oncol ; 25(5): 1242-1251, 2023 May.
Article em En | MEDLINE | ID: mdl-36547764
Colorectal cancer (CRC) is one of the common malignancies with a global trend of increasing incidence and mortality. There is an urgent need to identify new predictive markers and therapeutic targets for the treatment of CRC. Protease-activated receptors (PARs) are a class of G-protein-coupled receptors, with currently identified subtypes including PAR1, PAR2, PAR3 and PAR4. Increasingly, studies suggest that PARs play an important role in the growth and metastasis of CRC. By targeting multiple signaling pathways may contribute to the pathogenesis of CRC. In this review, we first describe recent studies on the role of PARs in CRC inflammation-cancer transformation, focusing on the important role of PARs in signaling pathways associated with inflammation-cancer transformation, and summarize the progress of research on PARs-targeted drugs.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Receptores Ativados por Proteinase / Neoplasias Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Receptores Ativados por Proteinase / Neoplasias Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article